
View larger version (175K):
[in a new window]
|
Fig. 4. RhoAN19 disrupts nonmuscle myosin II localization. Embryos expressing UAS-RhoAN19 under the control of enGAL4 (A,B,D,F) or prdGAL4 (C,E) were stained for nonmuscle myosin II. In all panels, bars indicate the extent of representative RhoAN19-expressing stripes. (A,B) During germband retraction, cells expressing RhoAN19 fail to ingress at the ventral midline and rather bulge, anteriorly and posteriorly, along the groove formed by neighboring wild-type cells. At higher magnification (B), nonmuscle myosin II appears less cortical and more cytoplasmic when compared with wild type. (C,E) During dorsal closure, nonmuscle myosin II is no longer highly concentrated at the leading edge of RhoAN19 stripes and these cells seem to spread forward over the amnioserosa. Arrowheads in the high-magnification view (E) indicate wild-type nonmuscle myosin II localization. (D,F) Leading edge cells expressing RhoAN19 also extend laterally, forming cell bridges. At this stage, cortical nonmuscle myosin II is clearly reduced in RhoAN19-expressing cells.
|